Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis (PSC) is a chronic, progressive fibro-inflammatory disease of the bile ducts that causes scarring, narrowing, and eventual destruction of the biliary system. It moves slowly but relentlessly — most patients live one to two decades after diagnosis before reaching end-stage liver disease. There is no pill that stops it, and a liver transplant is the only cure. Understanding PSC means understanding that biliary health, gut health, and liver health are deeply interconnected.

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Clinical Presentation
  5. Diagnosis
  6. Treatment
  7. Cholangiocarcinoma Surveillance
  8. Liver Transplantation
  9. Prognosis
  10. Research Papers
  11. Connections

Overview

Primary Sclerosing Cholangitis (PSC) is a chronic, progressive fibro-inflammatory disease of the biliary tract affecting both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile ducts. The hallmark of PSC is multifocal stricturing — segments of the bile ducts become inflamed, scarred, and narrowed, alternating with dilated segments upstream from the blockage. Over years to decades, this stricturing causes progressive biliary obstruction, biliary cirrhosis, and ultimately liver failure.

PSC carries several serious oncologic risks beyond liver failure itself:

PSC has an extraordinarily tight linkage with IBD: approximately 70% of PSC patients have coexistent IBD, predominantly ulcerative colitis (UC). Conversely, roughly 5% of patients with UC develop PSC. The relationship is asymmetric — IBD does not "cause" PSC and treating IBD does not alter PSC progression. PSC can precede, co-present with, or follow IBD diagnosis by years.

No medication has been proven to slow PSC progression or prevent transplant. Liver transplantation remains the only definitive treatment, with 5-year post-transplant survival of 80–85%.

Back to Table of Contents

Epidemiology

PSC is an uncommon disease with a distinctive demographic profile that sets it apart from its closest clinical sibling, Primary Biliary Cholangitis (PBC):

Geographic and ethnic variation is notable. PSC is more prevalent in Northern Europe and North America than in Asia or Africa. Within North America, White patients are diagnosed more frequently than Black or Hispanic patients, though ascertainment bias in IBD surveillance may partly account for this difference.

Back to Table of Contents

Pathophysiology

The exact mechanism driving PSC remains incompletely understood — it is one of the great unsolved problems in hepatology. Several overlapping hypotheses have generated the most compelling evidence:

The "Leaky Gut" and Gut–Liver Axis Hypothesis

The most widely accepted framework proposes that intestinal dysbiosis (disturbed microbial ecology, common in IBD) increases gut permeability. Microbial products — particularly bacterial lipopolysaccharide (LPS) and secondary bile acids — translocate through the intestinal mucosa into the portal circulation and reach the biliary epithelium. Cholangiocytes (bile duct lining cells) are then activated, triggering TGF-beta-mediated periductal fibrosis. On liver biopsy, this appears as concentric "onion-skin" fibrosis surrounding small bile ducts — pathognomonic when present.

Aberrant Lymphocyte Homing

Cholangiocytes in PSC aberrantly express CCL25 (a chemokine normally restricted to the gut) and MAdCAM-1. This creates a molecular "wrong address" signal: gut-primed T lymphocytes, which carry the integrin alpha4beta7 and CCR9 (homing receptors for the intestine), are incorrectly recruited to the liver via these ectopic signals. These misrouted immune cells accumulate around bile ducts and drive chronic inflammation. This hypothesis explains — at least partially — why PSC and IBD co-occur so strongly.

Biliary Epithelial Senescence

Cholangiocytes in PSC show markers of cellular senescence — irreversible growth arrest — and secrete a pro-inflammatory senescence-associated secretory phenotype (SASP). Senescent cholangiocytes generate reactive oxygen species (ROS) and pro-fibrotic mediators including TGF-beta1 and connective tissue growth factor (CTGF), accelerating periductal fibrosis even in the absence of active immune attack.

Genetic Architecture

PSC has strong HLA associations, confirming an immune-mediated component:

Serologic Markers

pANCA (perinuclear anti-neutrophil cytoplasmic antibody) is positive in 60–80% of PSC patients, but the target antigen is atypical — primarily anti-nuclear lamin B1 rather than myeloperoxidase (as in vasculitis). This "atypical pANCA" is a biomarker, not a pathogenic driver. Anti-mitochondrial antibody (AMA) — the hallmark of PBC — is absent in PSC, which is a critical distinguishing feature. IgG4 levels are elevated in a PSC subtype called IgG4-related sclerosing cholangitis, a distinct diagnosis that responds to steroids and is therefore critical to identify before labeling a patient with PSC.

Back to Table of Contents

Clinical Presentation

PSC is often a disease of two phases: a long silent phase detectable only through blood tests, followed by a symptomatic phase driven by biliary obstruction and its complications.

Asymptomatic Presentation (~50% at Diagnosis)

Half of patients are diagnosed incidentally — either during routine liver function tests that show an isolated elevation of alkaline phosphatase (ALP), or during IBD workup where liver enzymes are checked as a matter of protocol. These patients feel well and have no jaundice, pain, or itch at diagnosis.

Symptomatic Presentation

Biochemical Pattern

A cholestatic pattern is characteristic: ALP is typically elevated 3–10 times the upper limit of normal (ULN), GGT is similarly or more elevated, while bilirubin and transaminases (AST/ALT) are only mildly elevated in early disease. As cirrhosis develops, albumin falls and bilirubin rises, and transaminases may normalize paradoxically (reflecting loss of hepatocyte mass rather than improvement).

Dominant Stricture and Bacterial Cholangitis

A dominant stricture — a high-grade narrowing of the common bile duct or hepatic duct bifurcation — develops in 45–58% of patients. Downstream bile stasis predisposes to bacterial superinfection presenting with Charcot's triad: fever and rigors, right upper quadrant pain, and jaundice. Recurrent cholangitis accelerates fibrosis and is a significant independent predictor of poor prognosis.

Advanced Disease and Cirrhosis Complications

Back to Table of Contents

Diagnosis

The diagnosis of PSC rests on a combination of characteristic imaging, biochemical findings, and exclusion of mimics. No single test is 100% sensitive or specific.

Magnetic Resonance Cholangiopancreatography (MRCP)

MRCP is the first-line imaging study for suspected PSC. It is non-invasive and provides excellent visualization of bile duct architecture. The characteristic appearance is multifocal short strictures alternating with normal or dilated segments, producing a "string of beads," "pruned tree," or "beading" pattern throughout the biliary tree. Both intrahepatic and extrahepatic ducts are typically involved. MRCP is preferred as the initial test because it avoids the risks of ERCP (pancreatitis, cholangitis) while providing diagnostic-quality cholangiography.

Endoscopic Retrograde Cholangiopancreatography (ERCP)

ERCP remains the gold standard for cholangiographic detail and has the advantage of simultaneous therapeutic intervention. However, ERCP is reserved for cases where MRCP is non-diagnostic, where therapeutic dilation of a dominant stricture is planned, or where tissue sampling (brush cytology, fluorescence in situ hybridization [FISH] for chromosomal aneuploidy) is needed to evaluate for cholangiocarcinoma. ERCP carries a 3–5% risk of post-procedure pancreatitis and an elevated risk of bacterial cholangitis in PSC patients with bile stasis.

Liver Biopsy

Liver biopsy is not required for diagnosis when imaging is classic, but it provides staging information and may reveal pathognomonic "onion-skin" periductal concentric fibrosis around small bile ducts — present in only 10–40% of biopsies, making it insensitive but highly specific when found. Biopsy is most useful in small duct PSC (where MRCP is normal by definition), in suspected PSC-autoimmune hepatitis overlap syndrome, or to stage fibrosis for transplant listing.

Laboratory Tests

Differential Diagnosis: Secondary Sclerosing Cholangitis

Before diagnosing PSC, secondary causes of sclerosing cholangitis must be excluded:

Back to Table of Contents

Treatment

There is no proven disease-modifying pharmacologic therapy for PSC — a major unmet need in hepatology. Treatment is therefore directed at managing symptoms, preventing and treating complications, and planning for transplantation.

Ursodeoxycholic Acid (UDCA): Why It Is No Longer Recommended

UDCA at doses of 13–15 mg/kg/day improves liver biochemistry (ALP, GGT, bilirubin) and was widely used for years. However, a landmark multicenter randomized controlled trial by Lindor et al. (2009, Gastroenterology) found that high-dose UDCA (28–30 mg/kg/day) — while improving LFTs — significantly increased the risk of serious adverse events including death, liver transplantation, and development of esophageal varices compared to placebo. A systematic review of all UDCA trials in PSC found no survival benefit at any dose. UDCA is therefore no longer routinely recommended by the American Association for the Study of Liver Diseases (AASLD) or the European Association for the Study of the Liver (EASL) for PSC.

Endoscopic Therapy for Dominant Strictures

For patients with a symptomatic dominant stricture causing bacterial cholangitis, jaundice, or pruritus, endoscopic therapy via ERCP provides meaningful palliation:

Pruritus Management

  1. Cholestyramine 4 g before and after breakfast: first-line bile acid sequestrant; must be separated from other medications by 4 hours to avoid binding
  2. Rifampicin 150–300 mg twice daily: second-line; activates pregnane X receptor, accelerating bile acid catabolism; monitor LFTs for hepatotoxicity
  3. Naltrexone 50 mg daily: opioid antagonist targeting endogenous opioid-mediated itch; can cause opioid withdrawal symptoms at initiation (use low starting dose)
  4. Sertraline 75–100 mg daily: fourth-line; modest evidence from small RCTs

Fat-Soluble Vitamin Supplementation

Chronic cholestasis impairs fat-soluble vitamin absorption. Supplementation is individualized based on measured levels:

Bacterial Cholangitis Management

Management of Portal Hypertension Complications

Colorectal Cancer Surveillance in PSC-IBD

PSC with IBD carries a colorectal cancer risk roughly 4–10 times higher than IBD alone. Annual colonoscopy with chromoendoscopy (or extensive biopsies using the Seattle protocol) is recommended from the time of PSC diagnosis, regardless of IBD activity or duration.

Investigational Therapies

Active research areas in PSC include: FXR agonists (obeticholic acid — note: associated with worsening pruritus), nor-UDCA (norursodeoxycholic acid — Phase III trials ongoing), oral vancomycin (used in pediatric PSC with modest evidence), integrin antagonists (vedolizumab data mixed), and fecal microbiota transplantation (FMT — early phase trials). None is yet approved specifically for PSC.

Back to Table of Contents

Cholangiocarcinoma Surveillance

Cholangiocarcinoma (CCA) — bile duct cancer — is the most feared complication of PSC. PSC patients face a lifetime CCA risk of 10–15%, compared to a background rate of approximately 1–2 per 100,000 in the general population. CCA most commonly arises at the hilum (Klatskin tumor) in PSC, often within the first 2–3 years of PSC diagnosis — suggesting that some CCA arises in a field of already-dysplastic bile duct epithelium at the time PSC is first identified.

Recommended Surveillance Protocol

Evaluating a New Dominant Stricture for CCA

Any new dominant stricture in a known PSC patient must be presumed malignant until proven otherwise. Evaluation at ERCP should include:

Gallbladder Polyps

PSC patients have a higher rate of gallbladder polyps than the general population, and gallbladder carcinoma risk in PSC exceeds the general population several-fold. Any gallbladder polyp 8 mm or larger in a PSC patient warrants cholecystectomy. Annual ultrasound of the gallbladder is therefore integrated into PSC surveillance.

Back to Table of Contents

Liver Transplantation

Liver transplantation (LT) is the only definitive treatment for PSC. PSC represents 5–10% of all liver transplant indications in Western countries, making it one of the top five indications for adult liver transplant.

Indications and Timing

Post-Transplant Outcomes

IBD After Transplantation

A counterintuitive finding: IBD activity often worsens in PSC patients after liver transplantation, despite systemic immunosuppression. This is thought to relate to changes in bile acid composition post-transplant, altered microbiome, and immunosuppressive drug effects on mucosal immunity. Close gastroenterology surveillance is essential post-transplant, and annual colonoscopy is mandatory in PSC-IBD patients post-transplant indefinitely.

Back to Table of Contents

Prognosis

PSC is a heterogeneous disease: some patients remain stable for 15–20 years, while others progress to cirrhosis within 5 years. Predicting individual trajectory remains difficult.

Mayo Risk Score

The Mayo PSC Risk Score is the most validated prognostic model for short-to-medium term outcomes. It incorporates: age, serum bilirubin, AST, albumin, and history of variceal bleeding. Higher scores correlate with shorter transplant-free survival and are widely used in transplant listing decisions.

Prognostic Variables

Small Duct PSC

Small duct PSC (also called "pericholangitis") is a distinct variant in which MRCP is normal but liver biopsy shows periductal fibrosis affecting only the smallest intrahepatic bile ducts. It carries a markedly better prognosis than large duct PSC: median time to transplant or death exceeds 15 years in most series, and a subset of patients never progress. Approximately 12–25% of small duct PSC eventually evolves into large duct PSC over years of follow-up.

Leading Causes of Death

Median Transplant-Free Survival

Multiple population-based cohort studies from Scandinavia, the UK, and North America report a median transplant-free survival of 12–21 years from diagnosis. Quality of life is meaningfully impaired even in patients with stable biochemistry due to fatigue, pruritus, anxiety about cancer surveillance, and the logistical burden of concurrent IBD management.

Back to Table of Contents

Research Papers

Key PubMed searches for the primary literature on Primary Sclerosing Cholangitis:

  1. Primary sclerosing cholangitis pathogenesis review — PubMed
  2. PSC and inflammatory bowel disease epidemiology cohort studies — PubMed
  3. Ursodeoxycholic acid PSC randomized controlled trials — PubMed
  4. Cholangiocarcinoma risk and surveillance in PSC — PubMed
  5. MRCP accuracy for PSC diagnosis — PubMed
  6. Liver transplantation outcomes and PSC recurrence — PubMed
  7. PSC gut-liver axis microbiome dysbiosis — PubMed
  8. IgG4 sclerosing cholangitis vs PSC differential diagnosis — PubMed
  9. CA19-9 as biomarker for cholangiocarcinoma in PSC — PubMed
  10. Dominant stricture management with ERCP in PSC — PubMed
  11. Small duct PSC natural history and prognosis — PubMed
  12. Colorectal cancer risk and colonoscopy surveillance in PSC-IBD — PubMed

Back to Table of Contents

Connections

Back to Table of Contents